Pricing updated 2019-07-23. Prices are subject to change without notice.
Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor with key roles in adipocyte differentiation and glucose homeostasis.1,2 G3335 is a cell-permeable dipeptide that potently antagonizes PPARγ (Kd = 8.34 µM).3 It reversibly and competitively blocks activation of PPARγ by rosiglitazone (IC50 = 8-32 µM).3 G3335 is active in vivo, abolishing the protective effects of rosiglitazone in experimental spinal cord injury in rats.4 G3335 has also been used to evaluate the role of PPARγ in neurotoxicity studies.5,6
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
1. Heikkinen, S., Auwerx, J., and Argmann, C.A. PPARγ in human and mouse physiology Biochimica et Biophysica Acta 1771(8), 999-1013 (2007).
Michalik, L., Auwerx, J., Berger, J.P., et al. International union of pharmacology. LXI. Peroxisome proliferator-
Ye, F., Zhang, Z.S., Luo, H.B., et al. The dipeptide H-
4. Meng, Q.Q., Liang, X.J., Wang, P., et al. Rosiglitazone enhances the proliferation of neural progenitor cells and inhibits inflammation response after spinal cord injury Neuroscience Letters 503, 191-195 (2011).
Di Cesare Mannelli, L., Zanardelli, M., Micheli, L., et al. PPAR-
6. Zanardelli, M., Micheli, L., Cinci, L., et al. Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach PLoS One 9(7), 1-15 (2014).